Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Assetmark Inc.

Assetmark Inc. grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 83.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 16,454 shares of the medical equipment provider’s stock after buying an additional 7,462 shares during the quarter. Assetmark Inc.’s holdings in Zimmer Biomet were worth $1,501,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Zimmer Biomet by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock valued at $2,609,130,000 after purchasing an additional 166,763 shares during the period. Dodge & Cox lifted its stake in Zimmer Biomet by 2.3% in the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after buying an additional 446,018 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after acquiring an additional 3,208,596 shares during the period. JPMorgan Chase & Co. grew its position in shares of Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after acquiring an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Zimmer Biomet by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock valued at $233,009,000 after acquiring an additional 58,060 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $87.59 on Thursday. The firm has a market capitalization of $17.35 billion, a PE ratio of 21.31, a P/E/G ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 52 week low of $85.84 and a 52 week high of $114.72. The firm’s 50-day simple moving average is $100.84 and its 200 day simple moving average is $97.60. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the firm posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.39% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on ZBH shares. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 18th. Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. UBS Group boosted their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $110.63.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.